Bemcentinib Meets Efficacy Endpoint for High-Risk MDS and AML
Source: Pixabay.com

Bemcentinib Meets Efficacy Endpoint for High-Risk MDS and AML

Recently, biopharmaceutical company BerGenBio ASA ("BerGenBio") announced that their drug candidate bemcentinib reached its primary efficacy endpoint in a Phase 2 clinical trial. The drug is designed to treat patients…

Continue Reading Bemcentinib Meets Efficacy Endpoint for High-Risk MDS and AML

Virtual Event September 10th for Myeloproliferative Neoplasm International Awareness Day

Myeloproliferative neoplasm (MPN) International Awareness Day is on September 10th. This year, there will be a live streaming event to help bring awareness to this condition, instead of an in-person…

Continue Reading Virtual Event September 10th for Myeloproliferative Neoplasm International Awareness Day

She Survived the Lebanese Civil War and 30 Years of Challenges to Help Rett Syndrome Patients

Huda Zoghni was born in Lebanon. Huda attended medical school at the American University located in Beirut in 1975. According to an article in Discover, Huda was forced to leave…

Continue Reading She Survived the Lebanese Civil War and 30 Years of Challenges to Help Rett Syndrome Patients